HH-2301

N/A

Report date: 2022/06/13 16:49:32
NME

Base Information

Drug NameHH-2301
Drug Alias NameHH-2301HH2301
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmic
Therapy Area/IndicationsSolid tumoursBiliary Tract NeoplasmsGlioma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShangHai HaiHe Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShangHai HaiHe Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursBiliary Tract NeoplasmsGlioma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A